Brief: Morphosys’ Phase 3 Study Of Pelabresib In Myelofibrosis Demonstrates Statistically Significant Improvement

Morphosys AG

20/11/2023 21:44

Nov 20 (Reuters) - MorphoSys AG  MORG.DE :
    * MORPHOSYS’ PHASE 3 STUDY OF PELABRESIB IN MYELOFIBROSIS
DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN SPLEEN
VOLUME REDUCTION AND STRONG POSITIVE TREND IN SYMPTOM REDUCTION
    * MORPHOSYS AG - MANIFEST-2 MET PRIMARY ENDPOINT, NEARLY
DOUBLING
SVR35 RESPONSE RATE (66% VERSUS 35%)
    * MORPHOSYS AG - SAFETY RESULTS WERE CONSISTENT WITH PRIOR
CLINICAL TRIALS, WITH NO NEW SAFETY SIGNALS
    * MORPHOSYS AG - MORPHOSYS INTENDS TO SUBMIT FOR APPROVAL IN
U.S.
AND EUROPE IN MID-2024
    * MORPHOSYS AG - PELABRESIB PLUS RUXOLITINIB SHOWED
CLINICALLY
MEANINGFUL ANEMIA IMPROVEMENT VERSUS PLACEBO AND RUXOLITINIB

Source text for Eikon:  ID:nBw7QYqLSa 
Further company coverage:  MORG.DE 

 ((Reuters.Briefs@thomsonreuters.com;))